Skba Capital Management LLC Has $11.95 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Skba Capital Management LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 5.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 450,250 shares of the biopharmaceutical company's stock after acquiring an additional 21,400 shares during the period. Pfizer comprises about 1.9% of Skba Capital Management LLC's portfolio, making the stock its 20th largest holding. Skba Capital Management LLC's holdings in Pfizer were worth $11,945,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of PFE. Retirement Wealth Solutions LLC purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer during the fourth quarter valued at $32,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

PFE stock traded down $0.82 during midday trading on Tuesday, hitting $24.53. 54,333,514 shares of the company traded hands, compared to its average volume of 39,155,822. The business has a 50 day simple moving average of $26.05 and a 200-day simple moving average of $26.88. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market capitalization of $139.09 billion, a price-to-earnings ratio of 17.39, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The business's quarterly revenue was up 24.7% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Truist Financial lowered their target price on Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. UBS Group dropped their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Finally, Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is owned by insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.